Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07613099 · ClinicalTrials.gov registry record · Phase 3
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Not yet
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT07613099 is a Phase 3 study that has not yet begun recruiting, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 210 participants.
The verdict
NCT07613099, a Phase 3 study, has not yet begun recruiting, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help. Objective: To test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease. Eligibility: People aged 18 years and older with lung or heart disease that may cause scarring in those organs. Design: Participants will have 6 clinic visits over 2 years. Participants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart. The study tracer will be used with positron emission tomography (PET)/computed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine. Participants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits. Participants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated....
Interventions
- DRUG [18F]FAPI-74
- DIAGNOSTIC_TEST 18F-FAPI-74 PET/CT Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2033-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07613099
The ClinicalTrials.gov registry entry for NCT07613099 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [18F]FAPI-74 is the first listed.
NCT07613099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07613099 about?
NCT07613099 is a clinical study titled "Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging". Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still b...
What is the current status of trial NCT07613099?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2026-07-15. Estimated completion is 2033-05-26.
What interventions are being tested in trial NCT07613099?
The interventions under investigation include: [18F]FAPI-74 (DRUG), 18F-FAPI-74 PET/CT Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07613099?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.